Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase‐4 inhibitors and sulphonylureas: a primary care database analysis
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aims: To investigate therapy persistence, frequency of hypoglycaemia and macrovascular outcomes among type 2 diabetes patients with dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors ( DPP ‐4) and sulphonylureas ( SU ). Methods: Data from 19 184 DPP ‐4 (mean age: 64 years; 56% males) and 31 110 SU users (69 years; 51%) with new prescriptions (index date), without additional antidiabetics except metformin, in 1201 general practises in Germany were analysed. Therapy discontinuation (prescription gap >90 days), hypoglycaemia [International Classification of Diseases (ICD‐10)] and macrovascular outcomes ( ICD ‐10) (2‐year follow‐up) were compared adjusting for age, sex, diabetes duration, metformin, previous hypoglycaemia, health insurance, hypertension, hyperlipidaemia, antihypertensives, lipid‐lowering and antithrombotic drugs, microvascular complications and Charlson co‐morbidity score using logistic or Cox regression models. Results: Two years after index date, DDP ‐4 (non‐persistence: 39%) were associated with a lower risk of discontinuation compared to SU (49%) [adjusted hazard ratio ( HR ): 0.74; 95% confidence interval (CI): 0.71–0.76]. Hypoglycaemias (≥1) were documented in 0.18% patients with DPP ‐4 and in 1.00% with SU [odds ratio (OR): 0.21; 95% CI : 0.08–0.57]. Hypoglycaemias were significantly associated with incident macrovascular complications ( HR : 1.6; 95% CI: 1.1–2.2). Risk of macrovascular events was 26% lower in DPP ‐4 than in SU users. Conclusions: Lack of persistence with antidiabetic therapy is frequently found in primary care patients. DPP ‐4 was associated with lower therapy discontinuation and a fivefold reduced frequency of patients with hypoglycaemia compared to SU . The low absolute numbers of hypoglycaemias are most likely due to the fact that only severe events were documented. DPP ‐4 treatment was associated with reduced incidence of macrovascular events relative to SU in type 2 diabetes patients in primary care practises.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Phung, O. J. (2010) · JAMA · doi:10.1001/jama.2010.405 · Cited by 520
Tzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444
Karagiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012) · BMJ · doi:10.1136/bmj.e1369 · Cited by 435
Medication Adherence in Type 2 Diabetes: The ENTRED Study 2007, a French Population-Based Study
Tiv, M., Viel, J.-F., Mauny, F., Eschwège, E., Weill, A., Fournier, C., Fagot-Campagna, A., & Penfornis, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032412 · Cited by 245 · cited 1×
“Inadequate persistence reduces treatment effectiveness, leading to increased morbidity with considerable costs to the healthcare system [5].”
Background
Cited by
Amiel, S. A., Aschner, P., Childs, B., Cryer, P. E., de Galan, B. E., Frier, B. M., Gonder-Frederick, L., Heller, S. R., Jones, T., Khunti, K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30315-2 · Cited by 526
Goto, A., Arah, O. A., Goto, M., Terauchi, Y., & Noda, M. (2013) · BMJ · doi:10.1136/bmj.f4533 · Cited by 492
Iglay, K., Cartier, S. E., Rosen, V. M., Zarotsky, V., Rajpathak, S. N., Radican, L., & Tunceli, K. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1053048 · Cited by 157
Mattishent, K., & Loke, Y. K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.571568 · Cited by 69
Goto, A., Goto, M., Terauchi, Y., Yamaguchi, N., & Noda, M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002875 · Cited by 67
“ADVANCE (2010), Asia, Australia/ New Zealand, Canada, Europe3 58 66 5.0 (median) 11 140 8 (mean) 2.1 VADT (2011), USA2 97 60 5.6 (median) 1791 11.5 (mean) 5.8 Johnston et al. (2011), USA30 51 61 1.0 (mean) 860 845 NA 3.1 Zhao et al. (2012), USA31 96 63 3.9 (median) 1522 NA 1.7 Rathmann et al. (2013), Germany32 53 67 2…”
BackgroundInfluential
Metadata
- Authors
- Rathmann, W., Kostev, K., Gruenberger, J. B., Dworak, M., Bader, G., & Giani, G.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-09-09
- Volume
- 15
- Issue
- 1
- Pages
- 55-61
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2163153907
- Cited by
- 93
- References
- 7
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase‐4 inhibitors and sulphonylureas: a primary care database analysis. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01674.x
- The paper
- Rathmann, W., Kostev, K., Gruenberger, J. B., Dworak, M., Bader, G., & Giani, G. (2013). Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase‐4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01674.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.